Zoetis, a global leader in animal health, has announced its financial results for the fourth quarter and full year 2023, along with full-year guidance for 2024. In the fourth quarter of 2023, Zoetis reported revenue of $2.2 billion, marking an…
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has announced that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy. CASGEVY is now approved for treating patients aged 12 and older with severe sickle cell…
Bristol Myers Squibb has disclosed that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Augtyro™ (repotrectinib) to treat adult and pediatric patients aged 12 and above with solid tumors containing a neurotrophic…
Today marks the completion of AbbVie’s acquisition of ImmunoGen (NASDAQ: IMGN), solidifying ImmunoGen’s integration into AbbVie’s portfolio. Robert A. Michael, AbbVie’s president and chief operating officer, expressed enthusiasm about the merger, stating, “Together with ImmunoGen, we have the potential to…
Lupin Limited, a prominent global pharmaceutical company, has unveiled the launch of Bromfenac Ophthalmic Solution, 0.075%, following its approval by the United States Food and Drug Administration (U.S. FDA). This solution serves as a generic equivalent to BromSite® Ophthalmic Solution,…
CRISPR Therapeutics (Nasdaq: CRSP), a leading biopharmaceutical company dedicated to pioneering transformative gene-based therapies for serious illnesses, has announced a strategic move in securing approximately $280 million through a registered direct offering of its common shares. This offering, set at…
Today, Baxter, a prominent player in the global medtech arena, disclosed its financial outcomes for the fourth quarter and the entirety of 2023, concluding on December 31st. Additionally, the company outlined its financial projections for both the full-year and the…
Today’s announcement unveils Otsuka Foods’ plans to introduce five revamped Bon Curry NEO products, each boasting a richer flavor profile, all under the renowned Bon Curry brand. Set for release nationwide on Monday, March 4, 2024, these relaunched items mark…
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) has announced today the approval of crovalimab (known as 派圣凯® in China), a humanized complement inhibitor C5 monoclonal antibody developed by Chugai, by the National Medical Products Administration (NMPA) of the People’s Republic of…
Merck, a renowned science and technology enterprise, has announced the appointment of Michael Kleinemeier (66) as the Chair of its Supervisory Board. Kleinemeier, who previously served as a member of the Executive Board at SAP SE in the capacity of…
Eli Lilly and Company (NYSE:LLY) has announced that Philip Johnson, the group vice president and treasurer, will be retiring from the company after more than 28 years of service. His retirement is scheduled for the end of February, as he…
New data indicate that treatment with Nexviazyme® (avalglucosidase alfa) has significantly improved ptosis, or drooping eyelid, in pediatric patients with infantile-onset Pompe disease (IOPD) over nearly three years. These findings, presented at the 20th annual WORLDSymposiumTM, include positive safety results…